HUTCHMED (China) Ltd
- Last sale
- Nov 12, 2026 · -1.36%
- Market cap
- $2.60B
- 174.47M shares
- Filings
- 612
FY 2025−13.0% FY25 yoy
FY 2025+1,111.0% FY25 yoy
FY 2025N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
FY 2025+1,200.0% FY25 yoy
FY 2025−53.7% FY25 yoy
- $2.60B
- 5.7×
- 4.7×
- 2.1×
- -3.03%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $548,512,000 | reported | |
| FY 2024 | 2024-12-31 | $630,201,000 | reported | |
| FY 2023 | 2023-12-31 | $837,999,000 | reported | |
| FY 2022 | 2022-12-31 | $426,409,000 | reported | |
| FY 2021 | 2021-12-31 | $356,128,000 | reported | |
| FY 2020 | 2020-12-31 | $227,976,000 | reported | |
| FY 2019 | 2019-12-31 | $204,890,000 | reported | |
| FY 2018 | 2018-12-31 | $214,109,000 | reported | |
| FY 2017 | 2017-12-31 | $241,203,000 | reported | |
| FY 2016 | 2016-12-31 | $216,080,000 | reported | |
| FY 2015 | 2015-12-31 | $178,203,000 | reported | |
| FY 2014 | 2014-12-31 | $87,329,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2024 | — | $36.06M | $36.06M | — | 871.60M sh | +0.0% | — |
| FY2023 | — | $9.07M | $9.07M | — | 871.26M sh | +0.7% | 4.9% |
| FY2022 | — | $48.08M | $48.08M | — | 864.78M sh | +0.0% | — |
| FY2021 | — | $27.31M | $27.31M | — | 864.53M sh | +18.8% | — |
| FY2020 | — | $12.90M | $12.90M | — | 727.72M sh | +9.1% | — |
Segments
LineFY2025ShareChange
Oncology/Immunology segment$285.54M52%−21.4%
Other Ventures segment$262.97M48%−1.4%
Total$548.51M
Pharmaceutical preparations
HUTCHMED (China) Ltd is the 53rd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
TGTXTG Therapeutics, Inc.$616.3M87.3%72.6%$9.8BOPKOpko Health, Inc.$606.9M14.9%37.2%$1.2BINSMInsmed Inc$606.4M66.7%210.5%$25.9BORGOOrganogenesis Holdings Inc.$564.2M17.0%6.6%$125.3M
HCMHUTCHMED (China) Ltd (this company)$548.5M13.0%83.3%$2.6B
MIRMMirum Pharmaceuticals, Inc.$521.3M54.7%4.5%$6.1BBBIOBridgeBio Pharma, Inc.$502.1M126.3%144.4%$14.6BTVTXTravere Therapeutics, Inc.$490.7M110.5%5.2%$5.0BNATRNatures Sunshine Products Inc$480.1M5.7%4.1%$178.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
HUTCHMED (China) Ltd · CIK 1648257 · Engraved from SEC EDGAR